五年后,谁将是全球最畅销的药?谁将成为制药界的至尊王者?谁的管线资产今日潜龙在渊,明日就飞龙在天?一份最新的2030年预测榜单,正在悄然揭示未来制药世界的新秩序。GLP-1类药物全面主导榜单前列,礼来和诺和诺德一骑绝尘,从榜单十名开外跃升为全球制药行业之翘楚。当销售额、企业营收与管线价值三张榜单被摆在一起,答案已不再属于过去的制药逻辑。一场关于谁将统治2030的竞赛,已经鸣枪起跑。2030年全球最...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.